(Q38164663)

English

Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. (English)

1 reference

Europe PubMed Central

30 August 2017

methicillin-resistant Staphylococcus aureus

0 references

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

Patrick M McDaneld

1

1 reference

Europe PubMed Central

30 August 2017

Linda M Spooner

2

1 reference

Europe PubMed Central

30 August 2017

John F Mohr

3

1 reference

Europe PubMed Central

30 August 2017

Paul P Belliveau

4

1 reference

Europe PubMed Central

30 August 2017

language of work or name

0 references

publication date

1 November 2013

1 reference

Europe PubMed Central

30 August 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

30 August 2017

47

1 reference

Europe PubMed Central

30 August 2017

1654-1665

1 reference

Europe PubMed Central

30 August 2017

12

1 reference

Europe PubMed Central

30 August 2017

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007).

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin.

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Evaluation of vancomycin and daptomycin MIC trends for methicillin-resistant Staphylococcus aureus blood isolates over an 11 year period

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

In vitro activity of vancomycin and daptomycin against clinical isolates of Staphylococcus aureus and enterococci from India

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Molecular analysis and susceptibility patterns of meticillin-resistant Staphylococcus aureus (MRSA) strains circulating in the community in the Ligurian area, a northern region of Italy: emergence of USA300 and EMRSA-15 clones

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006–2008: Stratified analysis by vancomycin MIC

1 reference

https://api.crossref.org/works/10.1177%2F1060028013508272

21 January 2018

Identifiers

10.1177/1060028013508272

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38164663&oldid=1783927561"